DK3678687T3 - Mutant fgf-21 peptidkonjugater og anvendelser deraf - Google Patents

Mutant fgf-21 peptidkonjugater og anvendelser deraf Download PDF

Info

Publication number
DK3678687T3
DK3678687T3 DK18852510.9T DK18852510T DK3678687T3 DK 3678687 T3 DK3678687 T3 DK 3678687T3 DK 18852510 T DK18852510 T DK 18852510T DK 3678687 T3 DK3678687 T3 DK 3678687T3
Authority
DK
Denmark
Prior art keywords
peptide conjugates
mutant fgf
fgf
mutant
conjugates
Prior art date
Application number
DK18852510.9T
Other languages
English (en)
Inventor
Karla K Kopec
Patrick Mengyuan Liu
Original Assignee
89Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 89Bio Ltd filed Critical 89Bio Ltd
Application granted granted Critical
Publication of DK3678687T3 publication Critical patent/DK3678687T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
DK18852510.9T 2017-09-04 2018-09-04 Mutant fgf-21 peptidkonjugater og anvendelser deraf DK3678687T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762553970P 2017-09-04 2017-09-04
PCT/IB2018/001112 WO2019043457A2 (en) 2017-09-04 2018-09-04 CONJUGATES OF MUTANT PEPTIDE FGF-21 AND USES THEREOF

Publications (1)

Publication Number Publication Date
DK3678687T3 true DK3678687T3 (da) 2022-11-14

Family

ID=65525090

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18852510.9T DK3678687T3 (da) 2017-09-04 2018-09-04 Mutant fgf-21 peptidkonjugater og anvendelser deraf

Country Status (11)

Country Link
US (5) US10407479B2 (da)
EP (1) EP3678687B1 (da)
JP (1) JP6852939B2 (da)
KR (1) KR102229037B1 (da)
CN (2) CN114601932A (da)
AU (1) AU2018322943B2 (da)
CA (1) CA3074380C (da)
DK (1) DK3678687T3 (da)
ES (1) ES2930534T3 (da)
IL (1) IL272987B (da)
WO (1) WO2019043457A2 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11427623B1 (en) * 2019-05-28 2022-08-30 89Bio Ltd. Methods of treatment using mutant FGF-21 peptide conjugates
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
US20230090114A1 (en) * 2020-01-31 2023-03-23 89Bio Ltd. Methods for promoting weight loss
CN117120070B (zh) * 2021-03-11 2024-11-15 89生物公司 包含突变型fgf-21肽peg化缀合物的液体制剂
JP2024509950A (ja) * 2021-03-11 2024-03-05 89バイオ,インコーポレイテッド 変異体fgf-21ペプチドpeg化コンジュゲートを含む液体製剤
WO2023284822A1 (en) 2021-07-14 2023-01-19 Beijing Ql Biopharmaceutical Co., Ltd. Fusion polypeptides for metabolic disorders
IL317091A (en) 2022-06-24 2025-01-01 89Bio Inc Compositions and methods for treating severe hypertriglyceridemia
KR20250075578A (ko) * 2022-08-24 2025-05-28 89바이오 인코포레이티드 돌연변이 fgf-21 펩타이드 접합체를 사용한 nash의 치료 방법
WO2025043155A1 (en) * 2023-08-24 2025-02-27 89Bio, Inc. Therapeutic regimens and methods of treatment of nash using mutant fgf-21 peptide conjugates

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728554A (en) 1995-04-11 1998-03-17 Cytel Corporation Enzymatic synthesis of glycosidic linkages
US5876980A (en) 1995-04-11 1999-03-02 Cytel Corporation Enzymatic synthesis of oligosaccharides
US5922577A (en) 1995-04-11 1999-07-13 Cytel Corporation Enzymatic synthesis of glycosidic linkages
US6030815A (en) 1995-04-11 2000-02-29 Neose Technologies, Inc. Enzymatic synthesis of oligosaccharides
US6127153A (en) 1995-06-07 2000-10-03 Neose Technologies, Inc. Method of transferring at least two saccharide units with a polyglycosyltransferase, a polyglycosyltransferase and gene encoding a polyglycosyltransferase
AU736993B2 (en) 1997-01-16 2001-08-09 Novo Nordisk A/S Practical in vitro sialylation of recombinant glycoproteins
NZ522320A (en) 2000-05-12 2007-03-30 Neose Technologies Inc In vitro modification of glycosylation patterns of recombinant glycopeptides
EP2292273A3 (en) 2001-10-10 2011-11-23 BioGeneriX AG Remodeling and glycoconjugation of peptides
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
JP2005535280A (ja) 2001-11-28 2005-11-24 ネオーズ テクノロジーズ, インコーポレイテッド エンドグリカナーゼを用いる糖タンパク質のリモデリング
JP2005510229A (ja) 2001-11-28 2005-04-21 ネオーズ テクノロジーズ, インコーポレイテッド アミダーゼを用いる糖タンパク質のリモデリング
EP1504023A4 (en) 2002-05-03 2006-03-22 Neose Technologies Inc RECOMBINANT GLYCOSYL TRANSFERASE FUSION PROTEINS
EP1539989B1 (en) 2002-07-23 2011-04-20 BioGeneriX AG Synthesis of oligosaccharides, glycolipids and glycoproteins using bacterial glycosyltransferases
US7344858B2 (en) 2002-08-31 2008-03-18 Cj Corp Glycosylated human granulocyte colony-stimulating factor (G-CSF) isoform
NZ548893A (en) 2004-02-04 2009-09-25 Biogernerix Ag Methods of refolding mammalian glycosyltransferases
WO2005091944A2 (en) * 2004-03-17 2005-10-06 Eli Lilly And Company Glycol linked fgf-21 compounds
EP1814573B1 (en) 2004-10-29 2016-03-09 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
CN101516388B (zh) * 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
CA2682147C (en) 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
CN102037004A (zh) * 2008-01-08 2011-04-27 生物种属学股份公司 使用寡糖基转移酶的多肽的糖缀合
AU2010246038A1 (en) * 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
ES2534936T3 (es) 2010-08-02 2015-04-30 Ratiopharm Gmbh Método para producir y purificar una sialiltransferasa soluble activa
US8951966B2 (en) * 2011-07-01 2015-02-10 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
MX2017004947A (es) * 2014-10-24 2017-06-29 Bristol Myers Squibb Co Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.
RS59154B1 (sr) 2014-12-23 2019-10-31 Novo Nordisk As Fgf21 derivati i njihova upotreba
TW201731867A (zh) * 2015-12-02 2017-09-16 賽諾菲公司 Fgf21變異體

Also Published As

Publication number Publication date
EP3678687B1 (en) 2022-08-17
JP6852939B2 (ja) 2021-03-31
US20190389921A1 (en) 2019-12-26
IL272987B (en) 2022-08-01
AU2018322943B2 (en) 2020-06-04
EP3678687A2 (en) 2020-07-15
JP2020532579A (ja) 2020-11-12
AU2018322943A1 (en) 2020-04-16
CA3074380C (en) 2023-01-03
WO2019043457A3 (en) 2019-07-25
IL272987A (en) 2020-04-30
KR102229037B1 (ko) 2021-03-17
KR20200040307A (ko) 2020-04-17
US10407479B2 (en) 2019-09-10
CN111225683A (zh) 2020-06-02
US20190185533A1 (en) 2019-06-20
US20210355183A1 (en) 2021-11-18
WO2019043457A2 (en) 2019-03-07
CA3074380A1 (en) 2019-03-07
ES2930534T3 (es) 2022-12-16
CN114601932A (zh) 2022-06-10
EP3678687A4 (en) 2020-08-12
US20250333460A1 (en) 2025-10-30
US20240116995A1 (en) 2024-04-11
CN111225683B (zh) 2022-04-05

Similar Documents

Publication Publication Date Title
DK3784283T3 (da) Cannabidiopræparater og anvendelser deraf
DK3732185T3 (da) Konjugater og fremstilling og anvendelse heraf
DK3946464T3 (da) Forbindelser og konjugater deraf
DK3849614T3 (da) Interleukin-2-polypeptidkonjugater og anvendelser deraf
IL268593A (en) Polypeptide variants and uses thereof
DK3625263T3 (da) Anti-galectin- 9-antistoffer og anvendelser deraf
DK3641824T3 (da) Hydrofile linkere og konjugater deraf
DK3626825T3 (da) Anti-cdh6-antistof og anti-cdh6-antistof-lægemiddelkonjugat
IL291179A (en) Cnp variants and conjugates thereof
DK3383916T3 (da) Anti-CD73-antistoffer og anvendelser deraf
DK3610005T3 (da) Peptidligase og anvendelse deraf
DK3655401T3 (da) Tlr7/8-antagonister og anvendelser deraf
IL272987A (en) Mutant FGF-21 peptide conjugates and uses thereof
DK3458479T3 (da) Anti-b7-h3-antistoffer og antistof-lægemiddelkonjugater
IL275208A (en) Hsp90-targeting conjugates and formulations thereof
DK3380124T3 (da) Konjugater omfattende selv-immolative grupper og fremgangsmåder relateret dertil
DK3250237T3 (da) Hemiasterlinderivater til konjugering og terapi
IL270595B1 (en) Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
DK3596125T3 (da) Anti-PAR2-antistoffer og anvendelser deraf
IL283942A (en) Tubulysins and protein-tubulysin conjugates
IL277791A (en) HSP90 targeting conjugates and their formulations
DK3619324T3 (da) Rekombinante modificerede fibroblast-vækstfaktorer og terapeutiske anvendelser heraf
SG11202101517PA (en) Isoquinoline-steroid conjugates and uses thereof
DK3525826T3 (da) Ikke-lineære selvofrende linkere og konjugater deraf
DK3525828T3 (da) Anti-edb-antistoffer og antistoflægemiddelkonjugater